Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes.
作者信息
Tentolouris Anastasios, Eleftheriadou Ioanna, Tentolouris Nikolaos
机构信息
Diabetes Center, First Department of Propaedeutic Internal Medicine, Medical School, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
出版信息
Ann Transl Med. 2018 Feb;6(3):63. doi: 10.21037/atm.2017.12.28.
Abstract
摘要
相似文献
1
Insulin degludec U100 is associated with lower risk for severe and symptomatic hypoglycemia as compared with insulin glargine U100 in subjects with type 1 diabetes.与甘精胰岛素U100相比，德谷胰岛素U100在1型糖尿病患者中发生严重及有症状低血糖的风险较低。
Ann Transl Med. 2018 Feb;6(3):63. doi: 10.21037/atm.2017.12.28.
2
Cost-effectiveness of insulin degludec versus insulin glargine U100 in adults with type 1 and type 2 diabetes mellitus in Bulgaria.在保加利亚，1 型和 2 型糖尿病成人患者中，德谷胰岛素相对于甘精胰岛素 U100 的成本效益分析。
BMC Endocr Disord. 2019 Dec 3;19(1):132. doi: 10.1186/s12902-019-0460-6.
3
Cardiovascular Outcomes Trials Update: Insights from the DEVOTE Trial.心血管结局试验更新：来自 DEVOTE 试验的见解。
Curr Diab Rep. 2018 Sep 18;18(11):102. doi: 10.1007/s11892-018-1086-1.
4
Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).英国德谷胰岛素对比甘精胰岛素 U100 的长期成本效果：来自 DEVOTE 试验（DEVOTE16）基础-餐时亚组的证据。
Appl Health Econ Health Policy. 2019 Oct;17(5):615-627. doi: 10.1007/s40258-019-00494-3.
5
A short-term cost-utility analysis of insulin degludec versus insulin glargine U100 in patients with type 1 or type 2 diabetes in Denmark.丹麦1型或2型糖尿病患者中德谷胰岛素与甘精胰岛素U100的短期成本-效用分析
J Med Econ. 2017 Mar;20(3):213-220. doi: 10.1080/13696998.2016.1245663. Epub 2016 Oct 24.
6
The effect of insulin degludec on risk of symptomatic nocturnal hypoglycaemia in adults with type 1 diabetes and high risk of nocturnal severe hypoglycaemia (the HypoDeg trial): study rationale and design.德谷胰岛素对 1 型糖尿病成人患者夜间严重低血糖高风险及夜间症状性低血糖风险的影响（HypoDeg 试验）：研究原理和设计。
BMC Endocr Disord. 2019 Jul 23;19(1):78. doi: 10.1186/s12902-019-0408-x.
7
Effect of Insulin Degludec Versus Insulin Glargine U100 on Hypoglycemia in Hispanic Patients With Type 2 Diabetes: Results From the SWITCH 2 Trial.德谷胰岛素与甘精胰岛素U100对西班牙裔2型糖尿病患者低血糖的影响：SWITCH 2试验结果
Clin Diabetes. 2019 Jan;37(1):73-81. doi: 10.2337/cd18-0016.
8
Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study.住院 2 型糖尿病患者中，德谷胰岛素 U100 和甘精胰岛素 U100 联合餐时胰岛素注射的疗效和安全性：一项开放标签、随机对照研究。
Endocr J. 2019 Nov 28;66(11):971-982. doi: 10.1507/endocrj.EJ18-0309. Epub 2019 Jul 4.
9
Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.在心血管疾病高危的 2 型糖尿病患者中，德谷胰岛素与甘精胰岛素 U100 治疗心力衰竭的比较：DEVOTE 14 研究。
Cardiovasc Diabetol. 2019 Nov 15;18(1):156. doi: 10.1186/s12933-019-0960-8.
10
Patient-reported outcomes from a randomized, crossover trial comparing a pen injector with insulin degludec versus a pen injector with insulin glargine U100 in patients with type 2 diabetes.一项比较 2 型糖尿病患者使用笔式注射装置预填充德谷胰岛素与预填充甘精胰岛素 U100 的随机交叉试验的患者报告结局。
Curr Med Res Opin. 2019 Sep;35(9):1623-1629. doi: 10.1080/03007995.2019.1605769. Epub 2019 May 21.
引用本文的文献
1
The effect of insulin analogs in people with type 1 diabetes at increased risk of severe hypoglycemia.胰岛素类似物对严重低血糖风险增加的1型糖尿病患者的影响。
Front Pharmacol. 2023 Nov 27;14:1301931. doi: 10.3389/fphar.2023.1301931. eCollection 2023.
2
Comparison of treatment with insulin degludec and glargine U100 in patients with type 1 diabetes prone to nocturnal severe hypoglycaemia: The HypoDeg randomized, controlled, open-label, crossover trial.比较易发生夜间严重低血糖的 1 型糖尿病患者使用德谷胰岛素和 U100 甘精胰岛素治疗的效果：HypoDeg 随机、对照、开放标签、交叉试验。
Diabetes Obes Metab. 2022 Feb;24(2):257-267. doi: 10.1111/dom.14574. Epub 2021 Nov 2.
3
(Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.（超）长效胰岛素类似物用于 1 型糖尿病患者。
Cochrane Database Syst Rev. 2021 Mar 4;3(3):CD013498. doi: 10.1002/14651858.CD013498.pub2.
4
Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14.在心血管疾病高危的 2 型糖尿病患者中，德谷胰岛素与甘精胰岛素 U100 治疗心力衰竭的比较：DEVOTE 14 研究。
Cardiovasc Diabetol. 2019 Nov 15;18(1):156. doi: 10.1186/s12933-019-0960-8.
本文引用的文献
1
Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes.与 100U/mL 德谷胰岛素相比，1 型糖尿病患者每天接受 0.4U/kg 甘精胰岛素 300U/mL 治疗，其 24 小时药效动力学波动更小，药代动力学更平稳。
Diabetes Metab. 2018 Feb;44(1):15-21. doi: 10.1016/j.diabet.2017.10.001. Epub 2017 Nov 16.
2
Insulin Analogues and Hypoglycemia in Patients With Type 1 Diabetes.1型糖尿病患者中的胰岛素类似物与低血糖症
JAMA. 2017 Nov 14;318(18):1828. doi: 10.1001/jama.2017.14775.
3
Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.德谷胰岛素与甘精胰岛素U100对1型糖尿病患者低血糖的影响：SWITCH 1随机临床试验
JAMA. 2017 Jul 4;318(1):33-44. doi: 10.1001/jama.2017.7115.
4
Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.德谷胰岛素与甘精胰岛素治疗2型糖尿病的疗效和安全性比较
N Engl J Med. 2017 Aug 24;377(8):723-732. doi: 10.1056/NEJMoa1615692. Epub 2017 Jun 12.
5
Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes.临床试验中应报告低于3.0 mmol/L（54 mg/dL）的血糖浓度：美国糖尿病协会和欧洲糖尿病研究协会的联合立场声明
Diabetes Care. 2017 Jan;40(1):155-157. doi: 10.2337/dc16-2215. Epub 2016 Nov 21.
6
The beneficial effect of insulin degludec on nocturnal hypoglycaemia and insulin dose in type 1 diabetic patients: a systematic review and meta-analysis of randomised trials.德谷胰岛素对1型糖尿病患者夜间低血糖和胰岛素剂量的有益作用：一项随机试验的系统评价和荟萃分析
Acta Diabetol. 2015 Apr;52(2):231-8. doi: 10.1007/s00592-014-0604-0. Epub 2014 Nov 28.
7
Hypoglycaemia in diabetes mellitus: epidemiology and clinical implications.糖尿病患者的低血糖症：流行病学和临床意义。
Nat Rev Endocrinol. 2014 Dec;10(12):711-22. doi: 10.1038/nrendo.2014.170. Epub 2014 Oct 7.
8
A review of the pharmacological properties of insulin degludec and their clinical relevance.德谷胰岛素的药理学特性及其临床相关性综述。
Clin Pharmacokinet. 2014 Sep;53(9):787-800. doi: 10.1007/s40262-014-0165-y.
9
New insulin glargine 300 Units · mL-1 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units · mL-1.新的甘精胰岛素 300 单位/毫升与甘精胰岛素 100 单位/毫升相比，具有更平稳的作用谱和更持久的血糖控制。
Diabetes Care. 2015 Apr;38(4):637-43. doi: 10.2337/dc14-0006. Epub 2014 Aug 22.
10
Insulin degludec versus insulin glargine in type 1 and type 2 diabetes mellitus: a meta-analysis of endpoints in phase 3a trials.德谷胰岛素与甘精胰岛素治疗1型和2型糖尿病的疗效比较：3a期试验终点的荟萃分析
Diabetes Ther. 2014 Dec;5(2):435-46. doi: 10.1007/s13300-014-0076-9. Epub 2014 Aug 1.
Zotero 插件